2 weeks Ago By Defense World Staff
Brandes Investment Partners LP decreased its position in Takeda Pharmaceutical Company Limited ( NYSE:TAK – Free Report ) by 9.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,635,027 shares of the company’s stock after selling 267,480 shares during the period.
Brandes Investment Partners LP owned 0.08% of Takeda Pharmaceutical worth $34,048,000 as of its most recent SEC filing. Other hedge funds and other institutional investors have also made changes to their positions in the company.
Wells Fargo & Company MN raised its position in Takeda Pharmaceutical by 1.7% in the fourth quarter. Wells Fargo & Company MN now owns 774,552 shares of the company’s stock valued at $11,053,000 after purchasing an additional 12,756 shares during the period.
Capital Research Global Investors raised its holdings in Takeda Pharmaceutical by 3.6% in the 4th quarter. Capital Research Global Investors now owns 14,297,805 shares of the company’s stock valued at $204,030,000 after buying an additional 503,446 shares during the period.
OLD Mission Capital LLC lifted its position in Takeda Pharmaceutical by 1,440.9% in the fourth quarter. OLD Mission Capital LLC now owns 1,041,526 shares of the company’s stock valued at $14,863,000 after buying an additional 973,935 shares during the last quarter.
Leo Wealth LLC purchased a new position in Takeda Pharmaceutical during the fourth quarter worth about $1,919,000. Finally, NBC Securities Inc. boosted its stake in Takeda Pharmaceutical by 1.
8% during the first quarter. NBC Securities Inc. now owns 43,539 shares of the company’s stock worth $614,000 after buying an additional 765 shares during the period.
Institutional investors and hedge funds own 9.17% of the company’s stock. Takeda Pharmaceutical Price Performance Takeda Pharmaceutical stock opened at $14.
54 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.
74 and a current ratio of 1.26. The company has a market capitalization of $46.
02 billion, a price-to-earnings ratio of 26.44, a price-to-earnings-growth ratio of 0.27 and a beta of 0.
54. The company’s 50 day simple moving average is $14.45 and its 200-day simple moving average is $13.
75. Takeda Pharmaceutical Company Limited has a 1 year low of $12.57 and a 1 year high of $15.
63. Takeda Pharmaceutical Profile ( Free Report ) Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Further Reading Five stocks we like better than Takeda Pharmaceutical What Is WallStreetBets and What Stocks Are They Targeting? 3 Bargain Stocks Under $20 With Major Growth Potential How to Know Which Cryptocurrency to Buy: A Guide for Investors Top 5 ETFs to Own Now and Into 2025 What Are Some of the Best Large-Cap Stocks to Buy? Watch These 3 Former Short-Squeeze Stocks for a Big Rally Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Company Limited ( NYSE:TAK – Free Report ). Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.
com's FREE daily email newsletter ..
